Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Julie J. Exline, William A. Schutt, Kathleen C. Pait & Joshua A. Wilt. (2023) Do Psychedelic Trips Open the Door to Messages from God, Spirits, Transcendent Realities, or the Devil? Links with Attitudes About Psychedelics, Opinions About Legalization, and Interest in Personal Use. The International Journal for the Psychology of Religion 33:4, pages 361-379.
Read now
Read now
David E. Nichols. (2014) The Heffter Research Institute: Past and Hopeful Future. Journal of Psychoactive Drugs 46:1, pages 20-26.
Read now
Read now
Thomas Lyttle, David Goldstein & Jochen Gartz. (1996) Bufo Toads and Bufotenine: Fact and Fiction Surrounding an Alleged Psychedelic. Journal of Psychoactive Drugs 28:3, pages 267-290.
Read now
Read now
John H. Halpern. (1996) The Use of Hallucinogens in the Treatment of Addiction. Addiction Research 4:2, pages 177-189.
Read now
Read now
Articles from other publishers (26)
Justin N Bonnieux, Baeleigh VanderZwaag, Zahra Premji, Albert Garcia-Romeu & Mauricio A Garcia-Barrera. (2023) Psilocybin’s effects on cognition and creativity: A scoping review. Journal of Psychopharmacology 37:7, pages 635-648.
Crossref
Crossref
Justin Morales, Erik Quan, Arslaan Arshed & Ayana Jordan. (2022) Racial Disparities in Access to Psychedelic Treatments and Inclusion in Research Trials. Psychiatric Annals 52:12, pages 494-499.
Crossref
Crossref
Steven A. Barker. (2022) Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT. Psychopharmacology 239:6, pages 1749-1763.
Crossref
Crossref
David M. O’Shaughnessy & Ilana Berlowitz. (2021) Amazonian Medicine and the Psychedelic Revival: Considering the “Dieta”. Frontiers in Pharmacology 12.
Crossref
Crossref
David M. O’Shaughnessy, Ilana Berlowitz, Robin Rodd, Zoltán Sarnyai & Frances Quirk. (2021) Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine. Therapeutic Advances in Psychopharmacology 11, pages 204512532098663.
Crossref
Crossref
Annahita Nezami, Lisa Marie Persaud & Frank White. 2021. Expanding Worldviews: Astrobiology, Big History and Cosmic Perspectives. Expanding Worldviews: Astrobiology, Big History and Cosmic Perspectives
163
197
.
Jacob S. Aday, Cayla M. Mitzkovitz, Emily K. Bloesch, Christopher C. Davoli & Alan K. Davis. (2020) Long-term effects of psychedelic drugs: A systematic review. Neuroscience & Biobehavioral Reviews 113, pages 179-189.
Crossref
Crossref
Jamilah R. George, Timothy I. Michaels, Jae Sevelius & Monnica T. Williams. (2019) The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion. Journal of Psychedelic Studies 4:1, pages 4-15.
Crossref
Crossref
Timothy I. Michaels, Jennifer Purdon, Alexis Collins & Monnica T. Williams. (2018) Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. BMC Psychiatry 18:1.
Crossref
Crossref
Silvia N. Calderon, Joshua Hunt & Michael Klein. (2018) A regulatory perspective on the evaluation of hallucinogen drugs for human use. Neuropharmacology 142, pages 135-142.
Crossref
Crossref
Steven A. Barker. (2018) N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function. Frontiers in Neuroscience 12.
Crossref
Crossref
Christian Sueur. (2018) État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21 e siècle. Psychotropes Vol. 23:3, pages 125-163.
Crossref
Crossref
Robin M. Murray, Alessandra Paparelli, Paul D. Morrison, Arianna Marconi & Marta Di Forti. (2013) What can we learn about schizophrenia from studying the human model, drug-induced psychosis?. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 162:7, pages 661-670.
Crossref
Crossref
David J. Nutt, Leslie A. King & David E. Nichols. (2013) Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Reviews Neuroscience 14:8, pages 577-585.
Crossref
Crossref
Steven A. Barker, Ethan H. McIlhenny & Rick Strassman. (2012) A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010. Drug Testing and Analysis 4:7-8, pages 617-635.
Crossref
Crossref
J. C. Winter. (2008) Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology 203:2, pages 251-263.
Crossref
Crossref
MW Johnson, WA Richards & RR Griffiths. (2008) Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology 22:6, pages 603-620.
Crossref
Crossref
John C.M. Brust. 2007. Aspects neurologiques de l'addiction. Aspects neurologiques de l'addiction
315
334
.
Michael S. Jacob & David E. Presti. (2005) Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine. Medical Hypotheses 64:5, pages 930-937.
Crossref
Crossref
David E Nichols. (2004) Hallucinogens. Pharmacology & Therapeutics 101:2, pages 131-181.
Crossref
Crossref
John C.M. Brust. 2004. Neurological Aspects of Substance Abuse. Neurological Aspects of Substance Abuse
259
274
.
Nancy K. Morrison. 1998. Handbook of Substance Abuse. Handbook of Substance Abuse
229
240
.
Rick J. Strassman. (1995) Human psychopharmacology of N,N-dimethyltryptamine. Behavioural Brain Research 73:1-2, pages 121-124.
Crossref
Crossref
Richard H. Schwartz. (1995) LSD: Its Rise, Fall, and Renewed Popularity Among High School Students. Pediatric Clinics of North America 42:2, pages 403-413.
Crossref
Crossref
ROBERT S. GABLE. (2008) Regulatory Risk Management of Psychoactive Substances. Law & Policy 14:4, pages 257-276.
Crossref
Crossref
Timothy I. Michaels, Jennifer Purdon, Alexis Collins & Monnica Williams. (2018) Inclusion of People of Color in Psychedelic-Assisted Psychotherapy: A Review of the Literature. SSRN Electronic Journal.
Crossref
Crossref